Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos, Idenix Pen Hepatitis and HIV Drug-Discovery Pact

NEW YORK, Nov. 28 (GenomeWeb News) - Galapagos NV and Idenix Pharmaceuticals will collaborate on hepatitis and HIV infectious disease programs, Galapagos said last week.

 

Under the agreement, which is worth up to $2.5 million over two years, BioFocus, Galapagos' service division, will supply Idenix with its SoftFocus chemical compound collections. BioFocus will provide hit-to-lead and lead-optimization services.

 

Galapagos will receive technology access fees for SoftFocus, fee components for medicinal chemistry services, and success payments after identifying pre-clinical candidates. The amounts were not specified.